18 CONFIDENTIAL | --- | --- | |-------------------------------------|-------| | | | | Stratification Factors: | | | • Disease Location | | | (bone only vs. visceral) • Region | | PARCE SENICS MGD024 is investigational and has not yet been approved for marketing by any regulatory authority MACRO GENICS MGD024 MGD024: Favorable Cytokine Profile, Encouraging Combination Activity (in vivo) Improved Tolerability vs. Wild Type (WT) in Cynos 21 Preclinical data presented at ASH 2021 Interleukin-6 MGD024 Enhances A ...

MacroGenics, Inc. (NASDAQ:MGNX) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jim Karrels - Vice President, Chief Financial Officer Scott Koenig - President and CEO Conference Call Participants Jonathan Chang - SVB Securities Yigal Nochomovitz - Citi Kaveri Pohlman - BTIG Stephen Willey - Stifel Shay Simin - Barclays Operator Good afternoon. We will begin the MacroGenics 2023 First Quarter Corporate Progress and Financial Results Conference Call in just a moment. All participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpo ...

Developing Breakthrough Biologics, Life-changing Medicines® 2 DART, TRIDENT, MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc. All third-party trademarks used herein are registered trademarks of their respective owners. Integrated approach for exploiting direct and immune-based killing mechanisms Proof-of-Concept (Phase 2) Major Market Rights | --- | --- | --- | --- | --- | |--------------------------------|----------------------------------|-------- ...

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Call Participants Jonathan Chang - SVB Securities Etzer Darout - BMO Capital Markets David Dai - SMBC Jon Miller - Evercore ISI Stephen Willey - Stifel Boris Peaker - Cowen Silvan Tuerkcan - JMP Securities Operator Good afternoon. We will begin the MacroGenics 2022 Fourth ...

For the transition period from to Commission File Number 001-36112 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 (Exact name of registrant) MACROGENICS, INC. Indicate by check mark if the registrant is a well-known seasoned issuer, as defin ...

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Jim Karrels - SVP and CFO Dr. Scott Koenig - President and CEO Conference Call Participants Jessica Hui - Evercore Jonathan Chang - SVB Securities David Dai - SMBC Charles Zhu - Guggenheim Partners Silvan Tuerkcan - JMP Securities Operator Good afternoon. We will begin the MacroGenics 2022 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructi ...

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Chris James - VP, IR and Corporate Communications Scott Koenig - President and CEO Jim Karrels - CFO Conference Call Participants Jon Miller - Evercore ISI David Dai - SMBC Stephen Willey - Stifel Etzer Darout - BMO Capital Markets Faisal Khurshid - SVB Securities Operator Good afternoon. We will begin the MacroGenics' 2022 Second Quarter Corporate Progress and Financial Results Conference Call in ...

For the quarterly period ended June 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpor ...

MacroGenics, Inc. (NASDAQ:MGNX) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Chris James - Vice President, Investor Relations and Corporate Communications Scott Koenig - President and Chief Executive Officer Jim Karrels - Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Securities Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Peter Lawson - Barclays Stephen Willey - Stifel Jonathan Miller - Evercore ISI Yigal Nochomovitz - Citigroup David D ...